A randomised, placebo controlled pivotal trial of Ezutromid in patients
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 27 Jun 2018
At a glance
- Drugs Ezutromid (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Sponsors Summit Therapeutics
- 27 Jun 2018 According to a Summit Therapeutics media release, based on the results of the PhaseOut DMD 48-week data, the company has discontinued this drug development program, as, its primary and secondary endpoints has not been Met.
- 27 Jun 2018 Status changed from planning to withdrawn prior to enrolment, according to a Summit Therapeutics media release.
- 29 Jan 2018 New trial record